Big biotech, Big pharma, Biotech, Diagnostics, Partnering, Pharma

NanoString signs a pharma deal with Celegene

Posted on 04 June 2014

Tags: , ,

NanoString Technologies entered into a pharma deal with Celgene to develop a companion diagnostic assay using the nCounter Analysis System to support the clinical validation of REVLIMID for treatment of Diffuse Large B-Cell Lymphoma for $45 million.

NanoString will develop, seek regulatory approval for, and commercialize the diagnostic test and is eligible to receive payments totaling up to $45 million of which $5.75 million is an upfront payment, $17 million is for potential success-based developmental and regulatory milestones, and the remainder is for potential commercial payments.

DLBCL is a heterogeneous group of cancers classified together on the basis of morphology, immunophenotype, genetic alterations and clinical behavior, and represents the most common form of Non-Hodgkin Lymphoma.

NanoString will work to develop an in vitro diagnostic (IVD) companion test to REVLIMID that will be used to screen patients who are being enrolled in a pivotal study of REVLIMID for the treatment of DLBCL.

Upon successful completion of the study, NanoString will pursue regulatory approval of the IVD in key global markets.

NanoString retains the flexibility to independently develop and commercialize additional indications for the IVD assay.


Report: Partnering Deals and Alliances with Celgene

Report: Oncology Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply